AbstractDue to their targeted nature with high efficacy, biologics are progressively taking on a meaningful role in the treatment of common and/or serious diseases, despite their high development costs. With the expected expiry of the patents for many biologics, pharmaceutical companies are motivated to rapidly develop new biosimilars to increase the market access and affordability of these compounds. Recently the Food and Drug Administration approved Mvasi® as a biosimilar of Avastin®, which can potentially increase patients’ accessibility to an affordable alternative anti-cancer therapy and as a result improve clinical outcomes. Mvasi® is a biosimilar, which is similar to its originator biological, Avastin®, in terms of mechanism of action, quality, efficacy and tolerability. The approval process of biosimilars can be shorten by establishing biosimilarity between the biosimilar and the originator biologic. Although there is not much reduction in the manufacturing cost, the amount of clinical trials needed to access the safety and efficacy gets diminished through the abbreviated approval process. In the case of Mvasi®, it is still uncertain how much the costs may decrease, but the discount is estimated to be around 15 to 30%. ConclusionBiologics are medicines originated from living cells, with the help of highly complex and expensive manufacturing processes. At the moment, biological products, such as Avastin®, are the best-established class of binding molecules for treatment of different types tumors. Nevertheless, the high costs of these therapies limit the patients’ accessibility to these important and crucial anticancer therapies. Biosimilars offer an affordable alternative that can potentially increase patients’ accessibility to anticancer therapies and therefore improve clinical outcomes. A biosimilar, like Mvasi®, is truly what its name states — a drug that is “similar” to another biologic drug that has already been approved by the FDA in terms of mechanism of action, efficiency and toxicology. The biggest difference between Mvasi® and Avastin® lies in the economical aspect. The approval process of biosimilars can be shorten by establishing biosimilarity between the biosimilar and the originator biologic. Although there is not much reduction in the manufacturing cost, the amount of clinical trials needed to access the safety and efficacy gets diminished through the abbreviated approval process. In the case of Mvasi®, it is still uncertain how much the costs may decrease, but compared to other biosimilars already on the market, the overall discount is expected to be around 15 to 30%. Even the slightest discount can mean significant cost savings for patients, which can make Mvasi® more accessible and affordable than Avastin®.With the patent expiration of many biologics, it is expected that the market for biosimilars will become more prominent. The obligation to decrease healthcare costs and to increase patients’ accessibility to crucial therapies is an incentive for the develop of biosimilars. This may contribute to further reduce the price of biosimilars, making it more appealing for health insurers to reimburse the medicine. Biosimilars have a great chance of succeeding in the long run, but this will take considerable time and effort.